Prognostic factors in juvenile idiopathic arthritis

Current Rheumatology Reports

Volumn 3, Issue 5, 2001, Pages 371-378

  Prieur, Anne Marie ^a   Chèdeville, Gaëlle ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Ankylose Spondylitis; Autologous Stem Cell Transplantation; Juvenile Idiopathic Arthritis; Rheumatol; Uveitis

Indexed keywords

ADOLESCENT; AGE; CHILD; CLASSIFICATION; FEMALE; HOSPITALIZATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; ONSET AGE; PRACTICE GUIDELINE; PRESCHOOL CHILD; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ADOLESCENT; AGE FACTORS; AGE OF ONSET; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; GUIDELINES; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 0035486731     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-996-0006-6     Document Type: Article

References (59)

1. Ansell BM: Prognosis in juvenile arthritis. Adv Exp Med Biol 1999, 455:27–33.
2. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998, 25:1991–1994. The classification of childhood arthritis previously proposed at a meeting in Santiago in 1994 was reassessed at the second meeting of the Pediatric Standing Committee of ILAR held in Durban in 1997. This classification was discussed according to the opinion of different experienced pediatric rheumatologists from around the world and according to criticisms addressed to the Santiago proposals. A list of descriptors, i.e. characteristics that may be of importance for further definition of the disease were listed for each category.
3. Hofer M, Mouy R, Prieur AM: Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 2001, 28:1083–1090.
4. Lomater C, Gerloni V, Gattarina M, et al.: Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000, 27:491–496.
5. Cabane J, Michon A, Ziza JM, et al.: Comparison of long term evolution of adult and juvenile onset Still’s disease, both follow up for more than 10 years. Ann Rheum Dis 1990, 49:283–285. DOI: 10.1136/ard.49.5.283
6. Lin SJ, Chao HC, Yan DC: Different articular outcomes of Still’s disease in Chinese children and adults. Clin Rheumatol 2000, 19:127–130. DOI: 10.1007/s100670050030
7. Spiegel LR, Schneider R, Lang BA, et al.: Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000, 43:2402–2409. DOI: 10.1002/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C
8. Modesto C, Woo P, Garcia-Consuegra J, et al.: Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involvement as markers for bad prognosis. Clin Exp Rheumatol 2001, 19:211–217. From 124 patients with systemic onset observed in three different European centers, 91 were eligible for a retrospective evaluation of predictors for poor outcome by collecting clinical and laboratory features at onset, at 3 months, and at 6 months. The proposal of an easy clinical score from 0 to 6 at onset, if confirmed, should improve further strategies for these patients’ management.
9. Sharma S, Sherry DD: Joint distribution at presentation in children with pauciarticular arthritis. J Pediatr 1999, 134:642–643. DOI: 10.1016/S0022-3476(99)70254-4
10. Zak M, Pedersen FK: Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology 2000, 39:198–204. DOI: 10.1093/rheumatology/39.2.198
11. Guillaume S, Prieur AM, Coste J, Job-Deslandre C: Long term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. Arthritis Rheum 2000, 43:1858–1865. This study gathered together 207 patients observed in two pediatric rheumatology units in Paris. Clinical and laboratory data observed at onset were recorded. Other features at follow-up were the number of arthritis in a cumulative total, the occurrence of joint destruction on radiographs, and the presence of uveitis at systematic slit lamp examination. Multivariate analysis using the Cox model identified three independent factors of disease severity: two to four affected joints, upper limb involvement, and high ESR. DOI: 10.1002/1529-0131(200008)43:8<1858::AID-ANR23>3.0.CO;2-A
12. Musiej-Nowakoska E, Ploski R: Pregnancy and early onset pauciarticular chronic arthritis. Ann Rheum Dis 1999, 58:475–480. DOI: 10.1136/ard.58.8.475
13. Ravelli A, Viola S, Migliavacca D, et al.: The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999, 135:316–320. DOI: 10.1016/S0022-3476(99)70127-7
14. Woo P, Southwood TR, Prieur AM, et al.: Randomized, placebo-controlled, crossover trial low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000, 43:1846–1857. DOI: 10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F
15. David J, Cooper C, Hickey L, et al.: The functional and psychological outcomes of juvenile chronic arthritis in young adulthood. Br J Rheumatol 1994, 33:876–881. DOI: 10.1093/rheumatology/33.9.876
16. Kennedy LG, Will R, Calin A: Sex ratio in the spondylarthropathies and its relationship to phenotypic expression, mode of inheritance and age at onset. J Rheumatol 1993, 20:1900–1904.
17. Shore A, Ansell BM: Juvenile psoriatic arthritis: an analysis in 60 cases. J Pediatr 1982, 100:529–535. DOI: 10.1016/S0022-3476(82)80747-6
18. Hamilton ML, Gladman DD, Shore A, et al.: Juvenile psoriatic arthritis and HLA antigens. Ann Rheum Dis 1990, 49:694–697. DOI: 10.1136/ard.49.9.694
19. Roberton DM, Cabral DA, Malleson PN, Petty RE: Juvenile psoriatic arthritis: follow-up and evaluation of diagnostic criteria. J Rheumatol 1996, 23:166–170. A series of 63 patients with definite psoriatic arthritis (PsA) (50) and probable PsA (13), including 34 patients previously reported by Southwood et al., was analyzed after an average follow-up of 6.1 years. Probable PsA at onset in 11 of 24 patients evolved to definite PsA after a median of 2.1 years. The arthritis pattern of the patients remaining classified as probable PsA did not differ significantly from the group with definite PsA.
20. Rosenberg AM, Petty RE: A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982, 25:1041–1047. DOI: 10.1002/art.1780250902
21. Prieur AM, Listrat V, Dougados M, Amor B: Evaluation of four sets of criteria for spondylarthropathy in children: a multicentre European cross-sectional study. Arthritis Rheum 1992, 35:S190. DOI: 10.1002/art.1780350210
22. Edmonds J, Morris RI, Metzger AL, et al.: Follow-up study of juvenile chronic polyarthritis with particular reference to histocompatibility antigen W 27. Ann Rheum Dis 1974, 33:289–292. DOI: 10.1136/ard.33.4.289
23. Cabral DA, Oen KG, Petty RE: SEA syndrome revisited: a longterm follow-up of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992, 19:1282–1285. Thirty-six of 39 children from two centers in Canada initially described as having SEA syndrome were re-evaluated at 11-year follow-up. Among 13 patients who were originally reported has having definite spondylarthropathies, eight had AS, two had IBD, and three had initial reactive arthritis, of whom two were in remission and one had episodic arthritis. Among 23 with SEA syndrome, six had definite AS and six possible AS. The other patients had PsA, juvenile arthritis, SEA syndrome with sustained remission, or various other musculoskeletal conditions.
24. Burgos-Vargas R, Clark P: Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989, 16:192–197.
25. Burgos-Vargas R, Vazquez-Mellado J: The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995, 38:835–843. A retrospective review of the records from 35 patients with juvenile onset AS (New York criteria) and from 75 patients with juvenile arthritis excluding type II pauciarticular JA was done. Definite involvement of the spine and sacroiliitis in juvenile-onset AS occurred after a mean follow-up of 7.3 years. Tarsal disease was an important feature at AS onset, before the occurrence of axial involvement. DOI: 10.1002/art.1780380618
26. Kanski JJ: Uveitis in juvenile chronic arthritis. Clin Exp Rheumatol 1990, 8:499–503.
27. Akduman L, Kaplan HJ, Tyshsen L: Prevalence of uveitis in an outpatient juvenile arthritis clinic: onset of uveitis more than a decade after onset of arthritis. J Pediatr Ophthalmol Strabismus 1997, 34:101–106.
28. Haas JP, Truckenbrodt H, Paul C, et al.: Subtypes of HLA-DRB1*03, *08, *11,*13 and 14* in early onset pauciarticular juvenile chronic arthritis (EOPA) with and without iridocyclitis. Clin Exp Rheumatol 1994, 12:S7-S14.
29. Melin-Aldana H, Gianninni EH, Taylor J, et al.: Human leukocyte antigen DRB1*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. J Pediatr 1992, 121:56–60. DOI: 10.1016/S0022-3476(05)82541-7
30. Cabral DA, Petty RE, Malleson PN, et al.: Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol 1994, 21:2370–2375. Eighty-two eyes in 49 patients with chronic arthritis were studied after a mean follow-up of 9.4 years. More than 95% of the patients developed uveitis within 5 years of onset of arthritis. In 33% of the patients with ocular complications, normal vision was maintained or correctable in more than 50% of them.
31. Weiss AH, Wallace CA, Sherry DD: Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998, 133:266–268. DOI: 10.1016/S0022-3476(98)70232-X
32. Kilmartin DJ, Forrester JV, Dick AD: Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998, 82:737–742. DOI: 10.1136/bjo.82.7.737
33. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS: Visual outcomes prognosticators in juvenile rheumatoid arthritis associated uveitis. Ophthalmology 1997, 104:236–244.
34. Valimaki J, Airaksinen PJ, Tuulonen A: Molteno implantation for secondary glaucoma in juvenile rheumatoid arthritis. Arch Ophthalmol 1997, 115:1253–1256.
35. BenEzra D, Cohen E: Cataract surgery in children with chronic uveitis. Ophthalmology 2000, 107:1255–1260. DOI: 10.1016/S0161-6420(00)00160-3
36. Lundvall A, Zetterstrom C: Cataract extraction and intraocular lens implantation in children with uveitis. Br J Ophthalmol 2000, 84:791–793. DOI: 10.1136/bjo.84.7.791
37. Savolainen HA, Lehmati M, Kautiainen H, et al.: HLA-B27: a prognostic factor in juvenile chronic arthritis. Clin Rheumatol 1998, 17:121–124. DOI: 10.1007/BF01452257
38. David J, Vouyiouka O, Ansell BM, et al.: Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993, 11:85–90. This is the largest published series of patients with amyloidosis secondary to JIA. Treatment with chlorambucil appears to confer long-term survival and remission rates. Long-term side effects on fertility and the increased risk of malignancy deserve the consideration of other effective methods of suppressing the inflammatory process of JIA.
39. Duston MA, Skinner M, Shirahama T, Cohen AS: Diagnosis of amyloidosis by fat aspiration: analysis of four years’ experience. Am J Med 1986, 82:412–414. DOI: 10.1016/0002-9343(87)90439-6
40. Hawkins PN, Richarson S, Vigushin DM, et al.: Serum amyloid P component scintigraphy and turn over studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 1993, 36:842–845. DOI: 10.1002/art.1780360616
41. Laiho K, Tiitinen S, Kaarela K, et al.: Secondary amyloidosis has decreased in patients with joint disease in Finland. Clin Rheumatol 1999, 18:122–123. DOI: 10.1007/s100670050068
42. Bardare M, Falcini F, Hertzberger-Cate R, et al.: Idiopathic limb edema in children with chronic arthritis: a multicenter report of 12 cases. J Rheumatol 1997, 24:384–388.
43. Schmitt P, Prieur AM, Brunelle F: Juvenile rheumatoid arthritis and lymphedema: lymphangiographic aspects. Pediatr Radiol 1999, 29:364–366. DOI: 10.1007/s002470050608
44. Davies UM, Rooney M, Preece MA, et al.: Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. J Rheumatol 1994, 21:153–158.
45. Touati G, Prieur AM, Ruiz JC, et al.: Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy, I: Effects on growth velocity and body composition. J Clin Endocrinol Metab 1998, 83:403–409. Fourteen patients were treated with rhGH for 1 year. All patients showed an increase growth velocity from 1.9 to 5.4 cm/year. Lean body mass increased by 12.2% and fat mass excess decreased by 19.5%. After cessation of GH therapy, growth velocity and body composition returned to those before therapy. DOI: 10.1210/jc.83.2.403
46. Al-Mutair A, Bahabri S, Al-Mayouf S, Al-Mshwal A: Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. J Pediatr Endocrinol Metab 2000, 13:899–905.
47. Davies UM, Jones J, Reeve J, et al.: Juvenile rheumatoid arthritis: effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin binding proteins 1 and 3, and osteocalcin. Arthritis Rheum 1997, 40:332–340. DOI: 10.1002/art.1780400218
48. Falcini F, Ermini M, Bagnoli F: Bone turnover in children with juvenile rheumatoid arthritis. J Endocrinol Invest 1998, 21:31–36.
49. Zak M, Hassager C, Lovell DJ, et al.: Assessment of bone mineral density in adults with a history of juvenile chronic arthritis: a cross-sectional long-term follow up study. Arthritis Rheum 1999, 42:790–798. DOI: 10.1002/1529-0131(199904)42:4<790::AID-ANR24>3.0.CO;2-G
50. Rooney M, Davies UM, Reeve J, et al.: Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis. J Rheumatol 2000, 27:1073–1081.
51. Touati G, Ruiz JC, Porquet D, et al.: Effects on bone metabolism of one year recombinant human growth hormone administration to children with juvenile chronic arthritis undergoing chronic steroid therapy. J Rheumatol 2000, 27:1287–1293.
52. Glorieux FH, Bishop NJ, Plotkin H, et al.: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 339:947–952. DOI: 10.1056/NEJM199810013391402
53. Brumasen C, Hamdy NA, Papapoulos SE: Long-term effects of biphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997, 76:266–283. DOI: 10.1097/00005792-199707000-00005
54. Bianchi ML, Cimaz R, Bardare M, et al.: Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000, 43:1960–1966. DOI: 10.1002/1529-0131(200009)43:9<1960::AID-ANR6>3.0.CO;2-J
55. Lovel DJ, Gianninni EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342:763–769. Sixty-nine children with polyarticular course of JA were treated with etanercept 0.4 mg/kg twice weekly. Seventy-four percent met response criteria at day 90. In a second part of the study, randomized responders were treated with placebo or were continued on etanercept. Twenty-one of 26 patients receiving placebo had flares after a median time of 28 days, and seven of 25 patients receiving etanercept had flares after a median time of 118 days. DOI: 10.1056/NEJM200003163421103
56. Bloom BJ: Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000, 43:2606–2608. DOI: 10.1002/1529-0131(200011)43:11<2606::AID-ANR31>3.0.CO;2-X
57. Skytta E, Pohjanskovski H, Savoilainen A: Etanercept and urticaria in patients with juvenile arthritis. Clin Exp Rheumatol 2000, 18:533–534.
58. Elliott MJ, Woo P, Charles P, et al.: Suppression of fever and acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997, 36:589–596. DOI: 10.1093/rheumatology/36.5.589
59. Wulffraat NM, Sanders LAM, Kuis W: Autologous hematopoietic stem-cell transplantation for children with refractory autoimmune disease. Curr Rheumatol Rep 2000, 2:316–323. The authors present a comprehensive overview on the results of autologous stem cell transplantation (ASCT) in children with autoimmune diseases. Despite extremely encouraging results in JIA and in few children with SLE and scleroderma, this procedure remains very difficult with a high mortality rate. Proposals are discussed for reducing this very serious problem. DOI: 10.1007/s11926-000-0069-8